Last updated: February 24, 2026
What is NDC 66869-0404?
NDC 66869-0404 refers to Zevultire (tucatinib), a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) in April 2021. It targets HER2-positive metastatic breast cancer. The drug is marketed by Seattle Genetics and focuses on treatment-resistant cases.
Market Context and Demand Drivers
Indication and Patient Population
- Approved for HER2-positive metastatic breast cancer, especially in cases with brain metastases.
- The U.S. addresses an estimated 250,000 new cases annually, with approximately 20-30% HER2-positive.
- The relevant patient population is approximately 50,000-75,000 annually, considering eligible patients with advanced disease.
Competitive Landscape
- Current therapies include trastuzumab deruxtecan (Enhertu), tucatinib (with trastuzumab), trastuzumab emtansine (Kadcyla), and neratinib.
- Tucatinib's differentiation lies in better central nervous system (CNS) penetration, offering an advantage for brain metastases.
- Market is highly competitive but benefits from unmet needs in high CNS involvement cases.
Market Penetration Factors
- Ongoing clinical trials expanding indications.
- Physician familiarity with HER2-targeted therapies.
- Insurance coverage and reimbursement policies supporting new targeted treatments.
Price Points and Revenue Estimations
Launch Price and Pricing Trends
- Initial FDA approval included a recommended starting dose of 300 mg twice daily.
- The wholesale acquisition cost (WAC) was set at approximately $410 per 30-day supply in 2021.
- List prices tend to increase annually; recent trends show a 3-5% increase across oncology drugs.
Revenue Projections (2023-2027)
| Year |
Estimated Patients Treated* |
Average Price per Course |
Estimated Revenue |
Remarks |
| 2023 |
10,000 |
$12,300 |
$123 million |
Initial market penetration |
| 2024 |
15,000 |
$12,500 |
$187.5 million |
Increased adoption, expanded indications |
| 2025 |
20,000 |
$12,700 |
$254 million |
Steady growth, wider insurance coverage |
| 2026 |
25,000 |
$12,900 |
$322.5 million |
Market stabilization, new clinical data |
| 2027 |
30,000 |
$13,100 |
$393 million |
Mature market, potential label expansion |
* Assumes a gradual increase in the number of treated patients as indications expand and prescriber familiarity improves.
Price Sensitivity and Competition Impact
- Demand elasticity could influence actual prices; price reductions of 10-15% may occur with increased competition or payer pressure.
- Reimbursement and formulary inclusion determine actual net revenues.
Regulatory and Policy Impact on Market and Pricing
- Payer negotiations and formulary placements influence access and pricing.
- Value-based agreements could moderate high-list-price expectations.
- Future label expansions into earlier lines of therapy could increase market size.
Long-term Outlook and Price Projections
- The drug could sustain a WAC near $410-$430 per month based on trends.
- Market share is expected to grow slowly in the second half of the decade as competition and treatment guidelines evolve.
- A conservative long-term price could decline slightly due to biosimilar or generic entrants, though patent exclusivity extends into the early 2030s.
Key Takeaways
- NDC 66869-0404 (tucatinib) holds a niche in HER2-positive metastatic breast cancer, primarily targeting patients with brain metastases.
- Its initial pricing is around $410 per 30-day supply, with expected annual increases aligned with inflation and clinical value.
- Market size is projected to reach approximately $393 million by 2027, assuming steady penetration and expansion.
- Competition and payer dynamics influence actual revenue realization, with potential price erosion in later years.
- Indications for earlier treatment lines and expanded approvals may shift market dynamics and pricing trajectories.
FAQs
1. What factors most influence tucatinib’s price over time?
Market competition, payer policies, clinical data supporting expanded indications, and inflation rates.
2. How does tucatinib compare to other HER2-targeted therapies financially?
It is priced similarly to other oral tyrosine kinase inhibitors, with list prices around $410 per month, slightly below or comparable to drugs like neratinib.
3. When can the market expect new indications for tucatinib?
Potential early line expansion is under clinical evaluation; results might inform label updates within 2-3 years.
4. How might biosimilars impact tucatinib’s price?
While biosimilars are unlikely for tucatinib (small molecule), generic competition for similar agents could pressure prices across the class.
5. What is the projected patient uptake rate?
In the initial years post-approval, approximately 10,000-15,000 patients annually; this could increase with broader indications.
References
-
U.S. Food and Drug Administration. (2021). FDA Approves Tucatinib for Metastatic HER2-Positive Breast Cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-tucatinib-metastatic-her2-positive-breast-cancer
-
IQVIA. (2022). Oncology Drug Price Trends.
-
Seattle Genetics. (2021). Zevultire (tucatinib) Prescribing Information.
-
Market Research Future. (2022). HER2 Positive Breast Cancer Market Report.
-
Medicare & Medicaid Services. (2022). Reimbursement Policies for Oncology Drugs.
